Please login to the form below

Not currently logged in
Email:
Password:

Zytoprotec expands supervisory board

Prof Joerg Vienken and Prof Norbert Riedel join the firm

Zytoprotec Joerg VienkenZytoprotec has appointed Prof Joerg Vienken and Prof Norbert Riedel to its supervisory board.

Prof Vienken (pictured right) brings over 30 years of expertise in medical devices, biomaterials and artificial organs to the Austrian biotechnology company.

He served as vice president of biosciences at Fresenius Medical Care, a medical devices and services firm, as well as its global scientific ambassador between 1996 and 2013.

Prof Vienken currently holds teaching posts at technical universities RWTH Aachen, THM Giessen and TU Ilmenau and is a member of several scientific boards, including the Berlin-Brandenburg Center for Regenerative Therapies.

Zytoprotec Norbert RiedelMeanwhile, Prof Riedel (pictured left) moves to Zytoprotec from Baxter, where he most recently served as corporate vice president and chief science and innovation officer.

Since joining Baxter in 1998, Prof Riedel has also held the positions of president of Baxter's recombinant proteins business unit and vice president of research and development within its biosciences business.

Prior to this, he was head of worldwide biotechnology and core research functions at Hoechst Marion Roussel, now Sanofi-Aventis.

Prof Uwe Schlokat, chairman of Zytoprotec's supervisory board, said: “We are pleased that with Profs Vienken and Riedel Zytoprotec [we gain] two executive level research managers with backgrounds in product development in international life sciences companies and with unique scientific networks.

“With our lead product PD-protec reaching a key milestone on its way to market approval within 2016, we highly welcome the extensive industrial expertise that Profs Vienken and Riedel will bring to Zytoprotec.”

1st April 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics